Biopharming is the production and use of transgenic plants and animals genetically engineered to produce pharmaceutical substances for use in humans or animals. It often involves the insertion of gene constructs derived from humans. Biopharming exists on a spectrum of activity and is not clearly demarcated from its nearest neighbors. For example, genetically modified yeast, bacteria, and animal cell cultures have for some time been used to produce pharmaceutical substances in enclosed bioreactor systems, but are generally not included in the definition of biopharming. On the other hand, plant cell cultures, a newer development but also involving enclosed bioreactors, are typically included together with whole-plant methods in plant biopharming. While animals are also being genetically modified to alter their nutritional composition, to make them better models for human disease, and to provide more compatible organs for...
- Bovine Spongiform Encephalopathy
- Plant Cell Culture
- Zoonotic Disease
- Animal Cell Culture
- Animal Trial
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
APHIS (Animal and Plant Health Inspection Service). (2008). Guidance for APHIS permits for field testing or movement of organisms intended for pharmaceutical or industrial use. Washington, DC: United States Department of Agriculture.
APHIS (Animal and Plant Health Inspection Service) (n.d.). Biotechnology regulatory services: Noncompliance history. http://www.aphis.usda.gov/biotechnology/compliance_history.shtml. Accessed 4 Mar 2012.
Birnbacher, D. (2007). Pharming—ethical aspects. In M. Engelhardt et al. (Eds.), Pharming: A new branch of biotechnology (pp. 65–72). Bad Neuenahr-Ahrweiler: Europäische Akademie.
Bloomfield, B. P., & Doolin, B. (2011). Imagination and technoscientific innovations: Governance of transgenic cows in New Zealand. Social Studies of Science, 41, 59–83.
Borup, M., Brown, N., Konrad, K., & Lente, H. V. (2006). The sociology of expectations in science and technology. Technology Analysis & Strategic Management, 18, 285–298.
Brown, N. (2003). Hope against hype: Accountability in biopasts, presents and futures. Science Studies, 16, 3–21.
EFSA (European Food Safety Authority). (2009). Scientific opinion on guidance for the risk assessment of genetically modified plants used for non-food or non-feed purposes. The EFSA Journal, 1164, 1–42.
Einseidel, E. F., & Medlock, J. (2005). A public consultation on plant molecular farming. AgBioForum, 8, 26–32.
FDA (Food and Drug Administration). (2003). FDA investigates improper disposal of bioengineered pigs. http://www.fda.gov/cvm/Mar-Apr03.htm#2153. Accessed 09 Mar 2005.
Fiester, A. (2008). Justifying a presumption of restraint in animal biotechnology research. The American Journal of Bioethics, 8, 36–44.
Fischer, R., Schillberg, S., Hellwig, S., Twyman, R. M., & Drossard, J. (2012). GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnology Advances, 30, 434–439.
Goven, J., & Morris, C. M. (2012). Regulating biopharming: The prism of farmer knowledge. Science as Culture, 21, 497–527.
Laible, G., & Wells, D. N. (2007). Recent advances and future options for New Zealand agriculture derived from animal cloning and transgenics. New Zealand Journal of Agricultural Research, 50, 103–124.
Milne, R. (2010). Drawing bright lines: Food and the futures of biopharming. The Sociological Review, 58(S1), 133–151.
Milne, R. (2012). Pharmaceutical prospects: Biopharming and the geography of technological expectations. Social Studies of Science, 42, 290–306.
Müller-Terpitz, R. (2007). The use of genetically modified animals for the production of pharmaceuticals – legal considerations from an animal welfare perspective. In M. Engelhardt et al. (Eds.), Pharming: A new branch of biotechnology (pp. 73–87). Bad Neuenahr-Ahrweiler: Europäische Akademie.
Rehbinder, E., Engelhard, M., Hagen, K., Jørgensen, R. B., Pardo Avellaneda, R., Schnieke, A., & Thiele, F. (2009). Pharming: Promises and risks of biopharmaceuticals derived from genetically modified plants and animals. Berlin: Springer.
Rybicki, E. P. (2010). Plant-made vaccines for humans and animals. Plant Biotechnology Journal, 8, 620–637.
Sparrow, P. A., Irwin, J. A., Dale, P. J., Twyman, R. M., & Ma, J. K. C. (2007). Pharma-Planta: Road testing the developing regulatory guidelines for plant-made pharmaceuticals. Transgenic Research, 16, 147–161.
Taussig, K.-S. (2004). Bovine abominations: Genetic culture and politics in the Netherlands. Cultural Anthropology, 19, 305–336.
U.S. National Research Council Committee on Defining Science-based Concerns Associated with Products of Animal Biotechnology. (2002). Animal biotechnology: Science-based concerns. Washington, DC: National Academies Press.
Väliverronen, E. (2004). Stories of the “medicine cow”: Representations of future promises in media discourse. Public Understanding of Science, 13, 363–377.
Editors and Affiliations
Rights and permissions
© 2014 Springer Science+Business Media Dordrecht
About this entry
Cite this entry
Goven, J. (2014). Biopharming. In: Thompson, P., Kaplan, D. (eds) Encyclopedia of Food and Agricultural Ethics. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6167-4_175-5
Publisher Name: Springer, Dordrecht
Online ISBN: 978-94-007-6167-4
eBook Packages: Springer Reference Religion and PhilosophyReference Module Humanities and Social Sciences